Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
38.00
-1.50 (-3.80%)
Feb 21, 2025, 3:37 PM CET
-26.36%
Market Cap 177.21M
Revenue (ttm) 550.00K
Net Income (ttm) -18.37M
Shares Out 4.66M
EPS (ttm) -3.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,389
Average Volume 818
Open 38.30
Previous Close 39.50
Day's Range 37.80 - 38.30
52-Week Range 36.60 - 57.80
Beta 0.99
RSI 43.94
Earnings Date Apr 17, 2025

About Poltreg

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases. It engages in the research and development of therapies for the treatment of type 1 diabetes in children, and multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 23
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2023, Poltreg's revenue was 1.40 million, an increase of 40.04% compared to the previous year's 999,000. Losses were -13.55 million, 588.9% more than in 2022.

Financial Statements

News

There is no news available yet.